The Negative EtG and the Wife Who Disagrees
Marcus, 38, self-refers after his wife threatens to leave. He reports drinking "two or three beers" most evenings and denies any recent heavy use. AUDIT total 14, AUDIT-C 7. He had a witnessed withdrawal seizure during a prior quit attempt three years ago and takes no medications. He last drank 30 hours ago; CIWA-Ar is 6 (mild tremor, mild anxiety). A urine EtG drawn this morning is negative (<500 ng/mL); the specimen creatinine is 28 mg/dL, indicating a very dilute sample. His wife, without a signed release on file, reports he drank a pint of vodka daily until two days ago. He meets seven DSM-5-TR alcohol use disorder criteria and describes three months of daily worry and insomnia that began before his drinking escalated.
1. How do you reconcile the negative EtG with the collateral report and self-report, and what does that mean for your diagnosis and your documentation?
Read the worked answer
Interpret the test in context, not as a verdict.
- EtG is a monitoring biomarker with a detection window of roughly 80 hours, but it is subject to dilution. A creatinine of 28 mg/dL signals a very dilute specimen, which can push EtG below the 500 ng/mL cutoff even after drinking.
- A negative EtG never rules out alcohol use, and a positive one never proves a specific amount. Neither establishes or excludes a diagnosis.
Diagnosis rests on the clinical criteria. He meets seven of eleven DSM-5-TR criteria, which is severe alcohol use disorder regardless of the biomarker result. The EtG should not be used to downgrade the diagnosis, nor as a tool to "catch" him.
Handle the collateral carefully. The wife's report was given without a release; you may listen, but you may not confirm or discuss his care with her. Ask him to sign a release if he wants her involved, and use her information as one data point in a motivational conversation rather than as evidence to confront him.
Documentation. Record all three sources side by side, neutrally: self-report, dilute negative EtG with the creatinine caveat, and collateral (noting no release). Avoid language like "patient is dishonest." Document the reasoning that the diagnosis is criteria-based and unaffected by the assay.
2. What level of withdrawal management is appropriate, and why is the CIWA-Ar score not the deciding factor?
Read the worked answer
Do not let a low CIWA-Ar drive the disposition.
- The CIWA-Ar measures current symptom severity; it was not designed to determine level of care and can look reassuring early in the course.
- He is 30 hours from his last drink after heavy daily use, so he is entering the window in which withdrawal typically intensifies (roughly 24–72 hours).
- The prior witnessed withdrawal seizure is the decisive risk factor for complicated withdrawal, and it argues against unmonitored ambulatory detoxification.
Placement using ASAM criteria. With a history of withdrawal seizure plus ongoing heavy use, he warrants at least clinically managed residential withdrawal management with 24-hour monitoring (Level 3.2), and medically monitored or medically managed inpatient care (3.7 or 4) is defensible and often preferable. Level 1-D ambulatory withdrawal is not appropriate as a solo plan; if it were ever used, it would require daily medical contact, a reliable sober adult, and transport.
Medical adjuncts and handoff. Expect thiamine, folate, a multivitamin, electrolyte and liver function assessment, and a symptom-triggered benzodiazepine or phenobarbital protocol per facility policy. Once medically stable, transition to naltrexone or acamprosate plus behavioral treatment rather than discharge with no relapse-prevention plan.
3. He asks for a diagnosis of generalized anxiety disorder and a benzodiazepine "like his friend takes." How do you handle the co-occurring diagnosis?
Read the worked answer
Defer, do not dismiss.
- Anxiety, insomnia, and worry are core features of alcohol withdrawal and early abstinence and commonly persist for several weeks. Diagnosing an independent anxiety disorder during that window is unreliable.
- The fact that his worry predates the escalation of his drinking makes a true co-occurring disorder plausible, but plausibility is not a diagnosis.
Plan. Explain the timeline and agree to reassess in roughly 3–4 weeks of abstinence using a structured tool and functional impairment. Treat acute symptoms with nonpharmacologic measures, sleep hygiene, and behavioral activation now. If an independent anxiety disorder is confirmed later, SSRIs are first-line.
The benzodiazepine request. Say no clearly and give a reason he can hear: benzodiazepines carry a cross-tolerance and dependence risk in alcohol use disorder and can worsen outcomes. Offer the alternatives above and document the discussion and rationale.
Close the loop. Re-screen at the follow-up visit rather than leaving the question open, and coordinate with any future prescriber so a benzodiazepine is not started by another clinician without the history.